Medical News / AAAAI Congress 2021 - PONENTE: Benralizumab Reduces Oral Corticosteroid Use in Severe Asthmatics

Biologic therapy benralizumab (Fasenra) is associated with possible elimination or maximal reduction of oral corticosteroid (OCS) use in dependent patients with asthma, in new phase 3b data. The findings from the PONENTE Trial, presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2021 Virtual Sessions this weekend, evidence the AstraZeneca biologic’s benefit for reducing maintenance therapy needs in patients with severe asthma, regardless of baseline parameters including eosinophil counts. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

MORE MEDICAL NEWS
Omalizumab (Xolair) benefitted sleep disturbance among patients with nasal polyposis over a span of 76 weeks, ... read more
As covered by Lakiea Wright, MD, in a previous interview segment with HCPLive® during the American ... read more
A collection of articles published at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2021 ... read more
At the American Academy of Allergy, Asthma & Immunology (AAAAI) 2021 Virtual Sessions this weekend, a ... read more